Many patients with peripheral nerve diseases do not have a sufficient regenerative response because of genetic inheritance, infections or chronic disease, leading them to lifelong pain and disability.
Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.
Researchers from Poseida Therapeutics Inc. presented preclinical data for P-FVIII-101, a novel nonviral gene therapy being developed for the treatment of hemophilia A.
Adolore Biotherapeutics Inc. has offered an update on recent pipeline development progress as it advances nonopioid analgesic gene therapies for the treatment of chronic pain.
Sixpeaks Bio AG has emerged from stealth with $30 million in series A financing and a pipeline of therapies for healthy weight loss, including a dual-specific antibody targeting activin type IIA and B receptors for preservation of skeletal muscle mass.
Genmab A/S, in collaboration with Biontech SE, has presented data on a novel OX40 agonist antibody –Hexabody-OX40 (GEN-1055/BNT-315), developed using Genmab’s proprietary Hexabody platform, which promotes the formation of antibody hexamers upon target binding to cell surfaces.
U.S. Precision Medicine Inc. has announced plans to use artificial intelligence (AI) technology to support work on its small-molecule drug candidate for cancer.
Researchers from Uppsala University published data from a study that aimed to reveal and validate cancer vulnerabilities to immune checkpoint blockade (ICB) therapy in triple-negative breast cancer (TNBC). A human Tumor-Immune co-Culture System (TICS), which consisted of primary human lymphocytes from healthy blood donors co-cultured with human cancer cells, was optimized to perform mechanistic investigation of clinically approved ICB drugs.
RSS
